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Abstract: In this study, two DNA vaccines, which express the membrane (M) protein of 
porcine respiratory and reproductive syndrome virus (PRRSV) (pEGFP-M) and co-express 
both M and swine IL-18 (pEGFP-IL18-M), were constructed and their abilities to induce 
humoral  and  cellular  responses  in  piglets  were  comparatively  evaluated.  Experimental 
results showed that both recombinant DNA vaccines could not elicit neutralizing antibodies 
in  the  immunized  piglets.  However,  both  DNA  vaccines  elicited  Th1-biased  cellular 
immune responses. Notably, pigs immunized with the plasmid pEGFP-IL18-M developed 
significantly higher levels of IFN-γ and IL-2 production response and stronger specific 
T-lymphocyte proliferation response than the pigs inoculated with the plasmids pEGFP-M 
and pEGFP-IL18 (P < 0.05). These results illustrated that co-expression of M and IL-18 
proteins could significantly improve the potency of DNA vaccination on the activation of 
vaccine-induced  virus-specific  cell-mediated  immune  responses  in  pigs,  which  may   
be  used  as  a  strategy  to  develop  a  new  generation  of  vaccines  against  highly   
pathogenic PRRSV. 
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1. Introduction 
Porcine reproductive and respiratory syndrome (PRRS) is the most economically significant viral 
disease in the swine industry. It is characterized by respiratory illness in all age groups of swine leading 
to death in some younger pigs and severe reproductive problems in breeding age females. China not only 
is the biggest country of pig and pork production but also is the largest consumption market of pork in 
the world. Since PRRS outbreaks were first recognized in an intensive pig farms in North China at the 
end of 1995 [1], the disease has brought considerable loss to China’s swine industry each year although 
no  exact  amount  has  been  evaluated.  Since  then,  the  North  American  type  PRRSV  has  been 
predominantly circulating in China. In particular, a highly pathogenic PRRS broke out in the central 
region of China and has quickly spread throughout the country since 2006 [2,3]. The newly appearing 
PRRS caused high morbidity of 50–100% and a mortality rate of 20–100%. The high mortality in grown 
pigs is unusual and led to a countrywide epidemic of atypical PRRS. The highly virulent atypical PRRS 
occurred in many herds vaccinated with commercial PRRS vaccines, suggesting that the commercial 
vaccines were unable to protect pigs from PRRS [4].  
The causative agent, PRRS virus (PRRSV), is a positive sense RNA virus that groups within the order 
Nidovirales, family Arteriviridae. The genome of PRRSV is approximately 15 kb in length and contains 
nine open reading frames (ORFs). Currently, PRRSV includes two major antigenic types, the European 
type and the North American type. ORF1a and ORF1b encode viral replicase polyproteins that are 
immediately translated upon viral entry, and proteolytically processed by virally encoded proteinases 
into at least 13 mature nonstructural proteins (Nsps) [5–7]. ORF2a, ORF2b, ORF3 and ORF4 code for 
structural proteins GP2a, GP2b (E), GP3, GP4, respectively [8]. ORFs 5–7 encode three major structural 
proteins of virion: the envelope glycoprotein GP5, the non-glycosylated membrane protein (M) and the 
nucleocapsid protein (N), respectively [9]. Recently, a novel structural protein encoded by ORF5a was 
confirmed to play a significant role in PRRSV infection [10,11]. 
The  non-glycosylated  membrance  protein  (18–19  Da)  encoded  by  ORF6  contains  1–2  putative 
glycosylation sites and neutralizing epitopes [9,12]. The M protein is the most conserved structural 
protein between North American and European isolates. Of all the structural proteins, the M protein is 
the  most  potent  inducer  of  T  lymphocyte  proliferation  [13].  Thus,  M  protein  is  considered  very 
important in the arousal of cellular immune responses against PRRSV infection and may be an excellent 
candidate protein in the bioengineering of vaccine [14]. Vaccination with plasmid DNA encoding M 
protein may provide partial protection in pigs. 
In order to accelerate and magnify immune efficiency to PRRSV vaccine, several kinds of cytokines 
as adjuvants have been utilized to improve immune responses to PRRSV vaccines, including IL-2 [15,16], 
IL-12 [17], CD40 ligand [18], GM-CSF [19] and IL-18 [20]. Among them, Interleukin-18 (IL-18) has 
been widely used as adjuvant to enhance immune responses of many vaccine antigens. IL-18, also 
known as IFN-γ inducing factor, is a pleiotropic cytokine that plays an important role in both innate and 
acquired immunity [21,22]. But its function is mainly reflected in the T cell and the enhancement of 
cell-mediated immunity. In particular, IL-18 enhances cytotoxicity of NK cells and activator of the 
proliferation and the activity of T and NK cells [23,24]. Therefore, it is a good candidate for the 
modulation of immune responses and is employed as a DNA vaccine adjuvant in this study. Int. J. Mol. Sci. 2012, 13  5717 
 
In this study, two DNA vaccine constructs, expressing M protein of PRRSV alone (pEGFP-M) and 
co-expressing M  and swine  IL-18  proteins  (pEGFP-IL18-M), were constructed and  comparatively 
evaluated for their abilities to induce humoral and cellular responses in pigs, and what’s more, the effect 
of swine IL-18 in the modulation of a DNA vaccine-induced immune responses could be known. 
2. Results 
2.1. Construction and Expression of Recombinant Eukaryotic Plasmids 
As shown in Figure 1, under the control of CMV promoter, the recombinant plasmids pEGFP-M and 
pEGFP-IL18-M containing IL-18 and M genes with 15 amino acids linker (GGGGS)3 between them 
were constructed. The sequence analysis showed that the nucleotide sequences of the inserted genes in 
recombinant plasmids were the same as the original sequences and they were also inserted in the correct 
order in the plasmids.  
Figure  1.  Schematic  diagrams  of  recombinant  plasmids—pEGFP-M,  pEGFP-IL18  and 
pEGFP-IL18-M. pEGFP-N1 was used for the construction of the recombinant plasmids. 
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To determine whether the foreign genes could be expressed or not, MARC-145 cells were transfected 
with recombinant plasmids and the fluorescence were detected, because the cloned genes M and IL18-M 
were respectively co-expressed as fusions with  the N-terminus of EGFP respectively, as shown in  
Figure 1. Moreover, the transfected cells were collected and also verified by Western blotting. As shown 
in Figure 2, bright green fluorescence could be detected in MARC-145 cells respectively transfected 
with the two recombinant plasmids pEGFP-M and pEGFP-IL18-M, indicating that foreign genes M and 
M with IL-18 could be exactly expressed in mammalian cells. As shown in  Figure 3, two bands, 
approximately 49 kDa and 67 kDa, were respectively recognized by PRRSV-specific antibody in lysates 
of pEGFP-M and pEGFP-IL18-M transfected cells, proving that the foreign genes were indeed expressed 
in mammalian cells. Int. J. Mol. Sci. 2012, 13  5718 
 
Figure  2.  Fluorescent  photos  of  the  transfected  MARC-145  cells.  (A)  The  picture  of 
negative  control;  (B)  Green  fluorescence  images  of  cells  transfected  with  pEGFP-N1;   
(C)  Green  fluorescence  images  of  cells  transfected  with  pEGFP-M;  and  (D)  Green 
fluorescence images of cells transfected with pEGFP-IL18-M. 
    A  B 
D  C 
 
Figure 3. Western blot analysis of lysates of recombinant eukaryon expression plasmids 
transfected cells, pEGFP-IL18-M (lane 1), pEGFP-M (lane 2), pEGFP-N1 (lane 3), and 
negative control (lane 4). MARC-145 cells lysates without transfection were used as the 
control. Protein marker is shown on the right side. 
 
2.2. Humoral Immune Responses 
The  immunogenicity  of  recombinant  eukaryotic  expression  plasmids  were  examined  in  piglets.  
As shown in Figure 4, compared with the pigs vaccinated with pEGFP-IL18 and pEGFP-N1, detectable Int. J. Mol. Sci. 2012, 13  5719 
 
ELISA  antibody  in  pigs  vaccinated  with  pEGFP-M  and  pEGFP-IL18-M  increased  significantly, 
especially  after  the  booster  immunization  (P  <  0.05).  But  no  significant  difference  was  observed 
between the pEGFP-M and pEGFP-IL18-M groups (P > 0.05). 
Figure 4. M-specific enzyme-linked immunosorbent assay (ELISA) antibody responses in 
piglets  immunized  with  different  recombinant  plasmids.  Serum  samples  (n  =  5)  were 
collected  at  various  time  points  and  the  specific  antibodies  to  porcine  respiratory  and 
reproductive  syndrome  virus  (PRRSV)  were  measured  by  indirect  ELISA.  Data  are 
presented as the mean ±  S.D. Different letters (a, b) above the columns at the same time 
point indicate significant difference (P < 0.05) between the treatments. 
 
To further examine the protective neutralizing antibody, serum neutralizing (SN) antibody titres in 
the  vaccinated  pigs  were  also  monitored  after  primary  immunization.  Compared  with  the  pigs 
vaccinated with pEGFP-N1, no specific neutralizing antibodies were detected at all in pigs respectively 
inoculated with pEGFP-M and pEGFP-IL18-M till 42 days post primary-immunization. Throughout the 
assay, empty vector vaccination did not display any SN antibody activity. 
2.3. Lymphocyte Proliferation Responses 
The cell-mediated immune response was evaluated through PBMCs proliferation assay performed at 
14,  28  and  42  days  after  primary  immunization.  As  shown  in  Figure  5,  the  numerically  highest 
lymphocyte proliferation activity was observed in the group immunized with pEGFP-IL18-M, and after 
booster immunization, its stimulation index was significantly higher than those of the groups immunized 
with pEGFP-M and pEGFP-IL18 (P < 0.05). 
2.4. Cellular Immune Response 
To further evaluate cellular immune responses, the productions of IFN-γ and IL-2 in peripheral blood 
from the vaccinated piglets were examined. As shown in Figure 6, after booster immunization the levels Int. J. Mol. Sci. 2012, 13  5720 
 
of serum IFN-γ and IL-2 were significantly higher in the group that received pEGFP-IL18-M than the 
levels of serum IFN-γ and IL-2 in any other groups (P < 0.05). The results indicated that IL-18 had 
efficiently enhanced the cellular immune responses to M protein of PRRSV. 
Figure  5.  Lymphocyte  proliferation  responses  of  piglets  immunized  with  different 
recombinant plasmids. Blood samples (n = 5) were collected at various time-points and 
were stimulated with PRRSV protein in triplicate. Data are presented as the mean ±  S.D. 
Different letters (a, b, c) above the columns at the same time point indicate significant 
difference (P < 0.05) between the treatments. 
 
Figure 6. (A) IFN-γ level in peripheral blood from piglets inoculated with the recombinant 
plasmids (B) IL-2 level in peripheral blood from piglets inoculated with the recombinant 
plasmids. Different letters (a, b, c) above the columns at the same time point indicate 
significant difference (P < 0.05) between the treatments. 
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3. Discussion 
Currently no specific treatment is available for PRRS, so vaccination is an efficient strategy to control 
PRRS. There are two major categories of commercially available PRRSV vaccines: the modified-live 
virus (MLV) vaccine and killed-virus (KV) vaccine. KV vaccine could only provide partial immune 
protection to the Chinese highly pathogenic PRRSV [25]. Though PRRSV MLV vaccines confer solid 
protection against clinical disease induced by homologous infection, they have the potential to revert to 
virulence [26–28], restricting the application of this vaccination approach. Therefore, improved PRRSV 
vaccines or new generation vaccines against PRRSV need to be explored. Since IL-18 has previously 
been demonstrated to have potent adjuvant activity [20], we fused the porcine IL-18 gene with the 
PRRSV-M gene to enhance the immune responses to the M protein in the immunized pigs, resulting in 
the recombinant plasmid pEGFP-IL18-M. We not only addressed the adjuvant effect of IL-18 but also 
focused on the humoral and cellular immune responses generated by the M protein. 
Neutralizing antibody is a major component of humoral immunity that plays an important role in 
protection against PRRSV infection or reinfection, and in prevention or reduction of viral spread from 
pigs  to  pigs  [29,30].  In  this  study,  experimental  results  demonstrated  that  the  DNA  vaccines 
pEGFP-IL18-M and pEGFP-M could induce antibodies, but no specific neutralizing antibodies were 
detected in the sera of vaccinated piglets. Interestingly and coincidently, in previous reports, Kwang et al. 
reported that this absent antibody production was occasionally detected in the pigs immunized with 
plasmid DNAs expressing the M protein [31], and Zheng et al. also reported that no antibodies were 
detected when experimental mice were only infected with recombinant vaccinia virus expressing M 
protein alone [14]. Therefore, we concluded that the M protein expressed by plasmid DNA in this case 
was incompetent to induce protective neutralizing antibody in pigs.  
Cell-mediated immunity plays an important role against PRRSV infection. It has become evident that 
T cell-mediated immunity is essential for effective protection against PRRSV [32,33]. Coincidently, the M 
protein  is  the  most  conserved  structural  protein  and  the  most  potent  inducer  of  T  lymphocyte 
proliferation [13]. And the function of IL-18 (also known as IFN-γ inducing factor) is mainly reflected in 
the enhancement of cell-mediated immunity and in regulating both Th1- and Th2- driven immune 
responses [24]. To induce an effective cellular immune response is dependent on the specific cytokines 
produced during the infection, and the cytokine responses are mainly IFN-γ and to a lesser extent,  
IL-2 [34]. Furthermore, early studies showed that pigs recovering from experimental PRRSV infection 
had  strong  lymphocyte  proliferative  responses  [34,35].  Therefore,  in  order  to  evaluate  DNA 
vaccine-induced  PRRSV-specific  cell-mediated  response,  we  measured  T-lymphocyte  proliferation 
response,  IFN-γ  and  IL-2  production  responses.  The  experimental  results  demonstrated  that  all 
recombinant  plasmids  elicited  a  cell-mediated  immune  response,  but  pigs  immunized  with 
pEGFP-IL18-M developed significantly higher level of IFN-γ and IL-2 responses and had significantly 
stronger specific T-lymphocyte proliferation response than the pigs vaccinated with the pEGFP-M and 
pEGFP-IL18 (P < 0.05). It indicated that compared with the DNA vaccine of expressing M alone, 
porcine IL-18 when fused with PRRSV M protein had a significantly positive inductive effect on the 
activation of vaccine-induced virus-specific cellular immune responses in piglets. In addition, the M 
protein of PRRSV could only serve as a potent antigen for T cell-mediated immune responses but proved 
insufficient to induce protective neutralizing antibodies by itself.  Int. J. Mol. Sci. 2012, 13  5722 
 
It has been evident that M protein interacting with GP5 protein—a primary target of neutralizing 
antibody, can induce both good humoral immunity and cellular immunity. Zheng et al. reported that the 
recombinant vaccinia virus coexpressing the GP5 and M proteins generated more antibodies to the M 
protein in infected mice [14]. Moreover, Chia et al. reported that DNA constructs co-expressing GP5 
and M proteins of PRRSV were able to induce a strong PRRSV-specific cell-mediated immunity and 
antibody mediated immunity responses in pigs [36], and Jiang et al. reported that a suicidal DNA 
vaccine co-expressing a modified GP5 and M proteins of PRRSV also induced protective responses [37]. 
So co-expression of IL18-M protein and a modified GP5 protein may get better protective immunity 
than co-expression of M and modified GP5 protein, which would be a good subject for future research. 
And the identification of T-cell epitopes on the M protein of PRRSV may help us to better understand 
the cell-mediated immunity in protection against PRRSV.  
4. Materials and Methods 
4.1. Virus, Cells and Plasmid 
The PRRSV JL/07/SW strain was isolated by our research group from the brains and lungs of field 
pigs at the acute stage of PRRSV infection in Jilin province China, which was identified as a North 
American type isolate [38]. After cloning and sequencing its N gene, the result demonstrated that it had 
93.8% nucleotide sequence homology with North American PRRSVs, and 53.1% nucleotide sequence 
homology with European American PRRSV. The virus was propagated and titered on MARC-145 cells 
which  are  clones  of  MA-104  cells  highly  permissive  to  PRRSV  [39].  The  culture  method  for 
MARC-145 cells was carried out according to the method of Jiang et al. [40]. All expression plasmids 
were constructed using pEGFP-N1 as the basis vector. 
4.2. Construction of the Eukaryotic Expression Plasmids 
The  complete  coding  sequence  of  the  PRRSV  M  (ORF6)  gene  was  obtained  by  RT-PCR  
from  the  total  RNA  extracted  from  PRRS  virus-infected  cells,  using  specific  primers  (ORF6F: 
AAGCTTATGGGGTCGTCTCTA and ORF6R: GGATCCGGTTTGGCATATTTAAC). To facilitate 
the cloning of PCR products into the expression vector (pEGFP-N1), the recognition sequences for Hind 
III (AAGCTT) and BamH I (GGATCC) were designed into the corresponding forward and reverse 
primers. The PCR products were digested with the enzymes and finally inserted into the pEGFP-N1 
vector. IL-18 gene was obtained from the total RNA extracted from swine spleen lymphocytes. The 
extracted  RNA  was  used  as  template  for  a  RT-PCR  reaction  with  specific  primers  (IL-18F: 
GCACTCGAGATGTACTTGGCTA, IL-18R: GCGAAGCTTGGTGGAGGCGGATCCGGCGGAGGT 
GGCTCAGGCGGTGGCGGATCTTTTTGTTTTGA), which contains a flexible linker (Gly4Ser)3 [41]. 
The amplification product of IL-18 gene was cloned into the vector pEGFP-N1 by XhoI (CTCGAG) and 
Hind III (AAGCTT). For the construction of the eukaryotic expression plasmid pEGFP-IL18-M, the M 
gene  was  digested  with  HindⅢ  and  BamH  I  and  subcloned  into  the  plasmid  pEGFP-IL18.  All 
recombinant plasmids were confirmed by restriction digestion and sequence analysis. Int. J. Mol. Sci. 2012, 13  5723 
 
4.3. Identification of Expressions of M and M with IL-18 Proteins through Fluorescent Microscope and 
Western Blot 
MARC-145  cells  were  cultivated  on  a  concentration  of  2.5  ×   10
5  cells/well  in  a  6-well  tissue  
culture plate. Till the cells reaching approximately 70–80% confluence, the recombinant  plasmids 
pEGFP-IL18-M and pEGFP-M were respectively transfected into MARC-145 cells. Meanwhile the 
plasmid pEGFP-N1 was transfected into MARC-145 cells, used as positive control. Transfection was 
performed using LipofectAMINE 2000 Reagent (Invitrogen) according to the manufacturer’s instructions. 
The  transfected  cells  were  washed  once  with  PBS  (pH  7.4)  at  72  h  post  transfection  to  remove 
non-attached  cells  and  then  fluorescences  were  observed  by  an  inverted  fluorescent  microscope 
(Olympus). 
For Western bolt analysis, the transfected cells were treated according to the method of Hou et al. [42], 
and  finally  transferred  onto  nitrocellulose  membrane.  Then  the  membrane  was  incubated  with 
PRRSV-specific  antiserum,  followed  by  horseradish  peroxidase-conjugated  goat  anti-pig  IgG,  and 
followed by visualizing with DAB substrate. The untransfected MARC-145 cells lysates were used as 
negative control.  
4.4. Immunization of Pigs with the Recombinant Plasmids 
Twenty  30-day-old  crossbreed  (Landrace  ×   local  stock)  piglets  were  randomly  and  averagely 
separated into four groups and respectively fed in separate rooms. All piglets free of porcine pathogens 
included as category 1, 2 and 3 animal infectious diseases in Chinese government were also negative for 
PRRSV  tested  by  enzyme-linked  immunosorbent  assay  (ELISA).  Three  groups  were  respectively 
immunized with 1 mg of each DNA vaccine—plasmids pEGFP-M, pEGFP-IL18 and pEGFP-IL18-M. 
Another group was immunized with 1 mg of the empty vector pEGFP-N1. Booster immunization was 
conducted 21 days later. The injection route was direct inoculation of the plasmids into pigs’ neck 
muscles. Sera samples were collected at 0, 14, 28, 42 days after first immunization for indirect ELISA 
and serum neutralization assay. Furthermore, at 14, 28 and 42 days after first inoculation, blood samples 
were collected for lymphocyte proliferation assay and cytokine assay.  
4.5. Indirect ELISA  
Sera collected from experimental piglets at various time points were tested for the detection of 
specific antibodies by indirect ELISA, using purified SW/07/JL PRRSV as coating antigen. The 96-well 
ELISA plates were coated overnight at 4 °C  with 2 μg/mL of purified virus. Then plates were blocked 
for 1 h at 37 °C  with blocking buffer (2% BSA in PBST) and washed three times with PBST washing 
buffer. Then sera samples were made a 20-fold dilution in blocking buffer, then added to wells (100 μL 
per well) in duplicate, and incubated for 1 h at 37 °C . Followed by three washes, they were incubated 
with HRP-conjugated rabbit anti-porcine IgG for 1 h at 37 °C . Then the wells were washed three times 
again and handled according to the method of Li et al. [43]. Meanwhile, the sera of pigs negative for 
PRRSV antibodies were used as negative control. Int. J. Mol. Sci. 2012, 13  5724 
 
4.6. Serum Neutralization Assay 
Serum neutralization assays were performed according to previous description [44]. All samples 
were analyzed in triplicate. The neutralization titers were expressed as log2 of the reciprocal of the 
highest serum dilution in which no cytopathic effects was observed. 
4.7. Lymphocyte Proliferation Assay 
Lymphocyte proliferation assay was performed as previously described [20] with minor modifications. 
The peripheral blood mononuclear cells (PBMCs) were cultured in RPMI-1640 in 96-well plates at  
2 ×  10
5 cells/well in triplicate. Subsequently, the medium was respectively added with 20 μg/mL extracts 
of PRRSV-infected MARC-145 cells concentrated by ultracentrifugation at 80,000 ×  g for 2 h, with the 
cell lysate extracted from mock-infected MARC-145 as negative control. Meanwhile, 5 μg/mL ConA was 
added to a plate, which was used as the positive control. After incubation for 72 h at 37 °C  with 5% CO2, 
the proliferation responses were detected through MTT dye assay. At the end of the incubation, the 
plates were read at 490 nm. The stimulation index (SI) was calculated as the ratio of the average OD 
value of wells containing antigen-stimulated cells to the average OD value of wells containing cells 
cultured with medium alone. 
4.8. Cytokine Assay 
The evaluation of cellular immunity was performed through the detection of IFN-γ and interleukin-2 
(IL-2). Cytokine levels of IFN-γ and IL-2 were determined through the commercial cytokine ELISA 
Kits according to the manufacturer’s instruction (pig IFN-γ BMS671, sensitivity: 5 pg/mL, Bender 
MedSystems GmbH Campus Vienna Bio-center 2 A-1030 Vienna, Austria; porcine IL-2 ELISA Kit 
QS42565, sensitivity: 1.0 pg/mL, RapidBio Lab). 
4.9. Statistical Analysis 
All data were presented as mean ±  S.D. (standard deviation). The differences in the level of humoral 
and cellular immune responses between different groups were determined by analysis of variance and 
t-test. All data analyses were conducted by SPSS statistics software, Version 14.0. P-value < 0.05 was 
considered statistically significant. 
5. Conclusion 
Because China has a regulation that PRRSV vaccination-challenge experiment must be performed in 
bio-safety level-3 laboratory, it is impossible for us to evaluate its protection efficiency. However,  
we succeeded in  illustrating that  co-expression  of  M and  IL-18 proteins  could  show significantly 
stronger effects on the induction of vaccine-induced virus-specific cellular immune responses than 
expression of M alone.  Int. J. Mol. Sci. 2012, 13  5725 
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